Patients are at the mercy of choices pharmacies make
In a quiet but consequential act of public health, the FDA has recalled over 580,000 capsules of Teva's prazosin — a medication trusted by roughly half a million Americans to manage blood pressure and the tremors of trauma — after discovering elevated levels of nitrosamines, chemicals that accumulate silently and carry cancer's shadow. This recall is not an isolated incident but a chapter in a longer story about the hidden costs of pharmaceutical price competition, the globalization of drug manufacturing, and the gap between regulatory assurance and patient safety. The contamination, classified as a temporary risk rather than an emergency, nonetheless places hundreds of thousands of people in the uncomfortable position of weighing one harm against another.
- More than 580,000 capsules of a widely used blood pressure and PTSD medication have been pulled from shelves after cancer-linked chemicals were found at elevated levels inside them.
- Roughly 510,000 patients now face an unsettling choice: continue taking a potentially contaminated pill or risk dangerous rebound effects by stopping without medical guidance.
- Patients must act as their own detectives — checking bottle labels for 'MFG Teva' or NDC codes beginning with 0093 to determine whether their supply is part of the recall.
- The FDA's Class II classification signals a serious but non-catastrophic risk, and physicians can transition patients to alternatives like clonidine or a different prazosin manufacturer.
- A 2025 study showing generics made in India carry a 54% higher serious adverse event risk casts a long shadow over the recall, raising questions about whether price-driven pharmaceutical markets are quietly eroding drug safety.
Teva Pharmaceuticals is recalling more than 580,000 prazosin capsules after the FDA found elevated levels of nitrosamines — cancer-causing chemicals — in the generic medication used by approximately 510,000 Americans to treat high blood pressure and PTSD symptoms. The recall, announced in early October 2025, is the latest development in a contamination crisis that has quietly spread across the generic drug landscape since European regulators first discovered nitrosamines in the blood pressure drug valsartan in 2018.
Nitrosamines are not exotic poisons. They arise naturally in industrial chemical processes and appear in trace amounts in cured meats and chlorinated water. In small doses, they are largely harmless — but sustained exposure at elevated concentrations has been linked to cancer risk. Since the valsartan discovery prompted the FDA to begin systematic testing, contamination has surfaced in blood pressure drugs, diabetes medications, heartburn treatments, antibiotics, and smoking cessation aids, nearly always traced to manufacturing process failures.
Prazosin has been a generic drug for over 25 years, made by multiple manufacturers competing on price. Only Teva's version is affected, but patients must verify their supply. The label may read 'MFG Teva' or 'MFR Teva,' or the first four digits of the National Drug Code will be 0093. A pharmacist can confirm whether a specific lot number falls under the recall. Crucially, patients should not stop taking the medication without a doctor's guidance — abrupt discontinuation carries its own health risks, and physicians can often switch patients to alternatives or to a different prazosin manufacturer.
The recall carries a Class II designation, meaning the risk is considered temporary or reversible rather than immediately life-threatening. But the episode points toward a deeper structural problem. A 2025 study found that generics manufactured in India carry a 54% higher risk of serious adverse events than those made in the United States — a gap that widens the longer a drug has been on the generic market. When many manufacturers compete for the same low-margin product, quality control can become a casualty of cost-cutting. Teva has not disclosed where the recalled prazosin was produced. For now, half a million Americans must check their bottles, consult their pharmacists, and navigate an uncertainty that the current system was supposed to prevent.
Teva Pharmaceuticals' prazosin, a generic blood pressure and anxiety medication taken by roughly 510,000 Americans each year, is being pulled from shelves after the FDA discovered it contains elevated levels of nitrosamines—chemicals known to cause cancer when ingested in high doses over time. The recall, announced in early October 2025, affects more than 580,000 capsules. It is the latest in a widening pattern of contamination discoveries that has forced regulators and manufacturers to reckon with how generic drugs are made and where.
Nitrosamines are not exotic compounds. They form whenever a nitrite group—a common chemical building block—encounters an amine group in industrial settings. Rocket fuel plants, rubber manufacturers, and sealant producers all generate them as byproducts. Cured meats like bacon and pepperoni contain small amounts. Chlorinated water can produce trace quantities when it reacts with naturally occurring nitrogen-containing compounds. In small, occasional doses, nitrosamines pose little threat. But sustained exposure to high concentrations has been linked in some studies to cancer risk.
The drug industry's reckoning with nitrosamine contamination began in 2018, when European regulators testing the blood pressure drug valsartan found it laced with the chemical. The active ingredient had come from a Chinese manufacturer that sold to multiple companies, including Teva, triggering a cascade of recalls. That discovery prompted the FDA to launch a systematic hunt for nitrosamines across the prescription and over-the-counter landscape. The agency published initial testing guidance in 2021 and updated it in 2024. Since then, contamination has turned up in blood pressure drugs, diabetes medications, heartburn treatments, antibiotics, and smoking cessation aids—most traced back to chemical processing problems at manufacturing plants.
Prazosin itself has been available as a generic for more than 25 years, now made by multiple manufacturers competing on price. That competition, experts suggest, may be part of the problem. Teva's version is the only one contaminated, but patients need to verify which manufacturer supplied their pills. The prescription label contains clues: look for "MFG Teva" or "MFR Teva" under the manufacturer field, or check if the first four digits of the National Drug Code are 0093, which identifies Teva products. A pharmacist can cross-reference the lot number against the FDA's posted recall list.
The FDA classified this recall as Class II, meaning the contamination poses a temporary or reversible health risk—serious enough to warrant action, but not immediately catastrophic. Still, patients face a difficult calculus. Stopping prazosin abruptly can itself be dangerous; the drug manages both high blood pressure and post-traumatic stress symptoms, and discontinuing it without medical guidance risks rebound effects. The agency's guidance is clear: do not stop taking the medication without consulting a physician first. A doctor may be able to switch a patient to an alternative like clonidine or trazodone, or to a different generic version of prazosin from another manufacturer that remains in stock.
Behind this specific recall lies a larger question about generic drug safety and where American medications are made. A 2025 study found that generic drugs manufactured in India carry a 54 percent higher risk of serious adverse events compared to those made in the United States. The longer a drug has been on the market as a generic, the wider that safety gap grows. The pattern suggests that when many manufacturers compete for the same drug, lower-priced options win shelf space—and lower prices often mean corners cut in quality control. Teva operates manufacturing plants worldwide, including in India, but has not disclosed where the recalled prazosin was produced or where its ingredients came from.
The FDA rates generic drugs on quality, assigning an "A" rating to those meeting the same manufacturing standards and blood concentration levels as brand-name versions. But that rating tells pharmacies nothing about whether a drug came from a plant with a history of quality lapses. Patients, in effect, depend on pharmacy purchasing decisions they cannot see and cannot influence. If pharmacies had access to transparent information about manufacturing risk, they might make safer choices for their customers. For now, 510,000 Americans taking prazosin must check their bottles, contact their pharmacists, and decide with their doctors whether to continue, switch, or wait.
Citas Notables
If pharmacies could access reliable information about quality, they might be able to make choices that are safer for American consumers.— C. Michael White, Distinguished Professor of Pharmacy Practice, University of Connecticut
La Conversación del Hearth Otra perspectiva de la historia
Why does a drug that's been around for 25 years suddenly have this problem now?
It's not really sudden. The contamination was always there, probably. We just didn't have the testing framework to find it until 2018, when European regulators caught valsartan. That discovery opened everyone's eyes to how nitrosamines can slip into the manufacturing process. The FDA then built systematic testing requirements. Prazosin is one of many drugs that failed those new tests.
So the drug itself isn't the problem—it's how it's made?
Exactly. Prazosin the molecule is fine. But somewhere in the chemical processing at Teva's plant, nitrite and amine groups are meeting and forming something toxic. It's a manufacturing failure, not a design flaw.
Why is Teva's version contaminated but not the others?
That's the question nobody can fully answer without knowing where Teva sources its ingredients and which plant made theirs. Different manufacturers use different suppliers and processes. One plant's controls might catch the problem; another's might not.
The study about India-made generics—is that saying we shouldn't trust drugs from there?
Not exactly. It's saying that when you have price competition among many manufacturers, the cheaper options tend to win. And cheaper often means less rigorous quality control. India makes excellent drugs and poor ones. The issue is that we can't tell which is which because the FDA doesn't require transparency about where things are made.
So what should someone taking this prazosin actually do on Monday morning?
Check the label for Teva's name or NDC code 0093. If it matches, call the pharmacy and ask if that lot number is on the recall list. If it is, talk to your doctor before doing anything. Don't just stop. Your doctor might have you switch to another version, or to a different drug entirely. If no other option exists and the risk feels real, your doctor might say the nitrosamine exposure is worth it compared to stopping the blood pressure medication cold.
That's a grim choice.
It is. But it's the reality of how generic drugs work when there's no transparency about manufacturing.